Visual aura without headache as a pre‐cluster symptom in episodic cluster headache: A report of two cases

Author(s):  
Sylvain Redon ◽  
Marion Beltramone ◽  
Anne Donnet

Cephalalgia ◽  
2004 ◽  
Vol 24 (8) ◽  
pp. 631-638 ◽  
Author(s):  
K-H Lin ◽  
P-J Wang ◽  
J-L Fuh ◽  
S-R Lu ◽  
C-T Chung ◽  
...  

Cluster headache has not been fully investigated in Asians. One hundred and four patients (90M/14F; mean age 39.2 ± 12.2 years) with cluster headache were recruited from two major headache clinics in Taiwan. They filled out a structured cluster headache questionnaire. All participants were diagnosed to have episodic cluster headache. Mean age of onset was 26.9 years; mean latency of diagnosis was 8.1 years. A trend of decrease in male/female ratio with time was noted. Seventy-three percent were ex- or current smokers (M: 79%, F: 36%). Restlessness was reported by 51% patients. Only 1 patient (1%) reported visual aura. Patients responded well to standard acute and prophylactic treatment. The monthly incidence of cluster period was inversely related to sunshine duration. Compared to Western series, our patients were different in several aspects including the absence of chronic cluster headaches and a low prevalence of restlessness and aura. Racial and geographical factors might contribute to these discrepancies.



2021 ◽  
Vol 4 ◽  
pp. 251581632110156
Author(s):  
Brian Plato ◽  
J Scott Andrews ◽  
Mallikarjuna Rettiganti ◽  
Antje Tockhorn-Heidenreich ◽  
Jennifer Bardos ◽  
...  

Objective: The efficacy of galcanezumab was evaluated in patients with episodic cluster headache and history of preventive treatment failure. Methods: In the randomized, 8-week, double-blind study (CGAL), patients with episodic cluster headache received once-monthly subcutaneous injections of galcanezumab 300 mg or placebo. Patients who completed CGAL and enrolled in an open-label study were queried for preventive treatment history. In a subset of patients with a known history of failure of verapamil or any other prior preventive treatment, a post hoc analysis of least square mean change from baseline in weekly cluster headache attack frequency across Weeks 1 to 3 was assessed. Results: Fifteen patients provided data for known history of prior preventive treatment failure (6 placebo, 9 galcanezumab), of whom 11 failed verapamil. The mean reduction in the weekly frequency of cluster headache attacks was greater with galcanezumab compared to placebo among patients with prior preventive treatment failure (8.2 versus 2.4); mean difference 5.8 (95% confidence interval [CI] 2.0, 13.6) and among patients with verapamil failure (10.1 versus 1.6); mean difference 8.5 (95% CI 0.4, 16.7). Conclusion: In this exploratory analysis of patients with a known history of prior preventive treatment failures, treatment with galcanezumab resulted in greater mean reductions in weekly cluster headache attacks compared with placebo. ClinicalTrials.gov: NCT02397473 (I5Q-MC-CGAL) NCT02797951 (I5Q-MC-CGAR)



2018 ◽  
Vol 1 ◽  
pp. 251581631880969
Author(s):  
Cherubino Di Lorenzo ◽  
Lanfranco Pellesi ◽  
Gianluca Coppola ◽  
Vincenzo Parisi ◽  
Maurizio Evangelista ◽  
...  

Cluster headache (CH) is one of the most severe forms of headache, but the number of effective treatments is still limited. Recently, we reported the case of a drug-resistant CH patient responsive to the rotigotine transdermal patch, which is used in the treatment of Parkinson’s disease. This report formed the basis for a case series where other drug-resistant CH patients were treated with rotigotine. Here are the results of this study. Twenty-two CH patients underwent the treatment. Eight were episodic cluster headache (ECH) patients and 14 were chronic cluster headache (CCH) patients. Of the eight ECH patients, four reported that their CH had been stopped by the treatment. Of the 14 CCH patients, 11 were considered responders to the treatment (5 experienced a full resolution of headache, and 6 had a headache reduction of at least 50% in terms of mean monthly number of attacks). Our case series confirms the previous observation that rotigotine could be helpful in the treatment of CH. It may even influence the monoaminergic system that has a key role in the pathogenesis of CH.



1996 ◽  
Vol 36 (6) ◽  
pp. 389-391 ◽  
Author(s):  
V. Centonze ◽  
B.M. Polito ◽  
E. Attolini ◽  
M.A. Cassiano ◽  
C. Sabba ◽  
...  


1985 ◽  
pp. 283-289 ◽  
Author(s):  
G. Sandrini ◽  
G. Micieli ◽  
E. Martignoni ◽  
G. Bono ◽  
F. Savoldi ◽  
...  


1985 ◽  
pp. 269-275 ◽  
Author(s):  
G. Nappi ◽  
F. Facchinetti ◽  
G. Bono ◽  
F. Petraglia ◽  
G. Micieli ◽  
...  


2020 ◽  
Vol 60 (10) ◽  
pp. 2254-2264
Author(s):  
David Kudrow ◽  
J. Scott Andrews ◽  
Mallikarjuna Rettiganti ◽  
Tina Oakes ◽  
Jennifer Bardos ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document